Related Experiment Video

Updated: Aug 6, 2026

Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice
05:12

Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice

Published on: August 13, 2015

The interplay between platelet and vessel-wall mediators in coronary artery occlusion

P Vallance1

  • 1Department of Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, London, UK.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1989
PubMed

Insights

Myocardial infarction involves platelet aggregation and vasospasm due to mediator imbalance. Restoring this balance, particularly with nitric oxide, may be key for therapeutic intervention in heart attacks.

Area of Science:

  • Cardiovascular Medicine
  • Platelet Biology
  • Endothelial Function

Background:

  • Myocardial infarction (MI) is linked to platelet aggregation and coronary vasospasm.
  • Endogenous mediators from platelets and vessel walls influence platelet function and vascular tone.
  • These mediators play a role in the myocardial infarction process.

Purpose of the Study:

  • To explore the role of endogenous mediators in myocardial infarction.
  • To understand how platelet-vessel wall interactions influence mediator balance.
  • To identify therapeutic targets for restoring mediator balance in MI.

Main Methods:

  • Analysis of mediator synthesis and actions at sites of endothelial damage.
  • Investigating the balance of mediators favoring aggregation and vasospasm.
  • Focus on interactions between platelets and the vessel wall.

Main Results:

  • MI occurs at endothelial cell damage sites.
  • The balance of mediators shifts towards aggregation and vasospasm in MI.
  • Platelet-vessel wall interactions are crucial in determining mediator balance.

Conclusions:

  • Therapeutic strategies for MI should focus on restoring mediator balance.
  • Manipulation of endothelium-derived nitric oxide is a potential therapeutic avenue.
  • Targeting intracellular second messengers of nitric oxide may be beneficial in treating MI.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...